<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00542555</url>
  </required_header>
  <id_info>
    <org_study_id>HCT3012-X-301/301E</org_study_id>
    <nct_id>NCT00542555</nct_id>
  </id_info>
  <brief_title>Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee</brief_title>
  <official_title>301: A Phase 3 Study of the Analgesic Efficacy and Safety of HCT 3012: A Parallel, Randomized, Double Blind, 13 Week Placebo and Naproxen Controlled, Multicenter Study of HCT 3012 (375 mg Bid and 750 mg Bid) in Patients With Osteoarthritis of the Knee, Followed by Its Extension (301E): A Parallel, Randomized, Open-Label, Multicenter, 52-Week Follow-up Safety Study of HCT 3012 (375 mg Bid and 750 mg Bid) in Subjects With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NicOx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NicOx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the efficacy and safety of naproxcinod vs. placebo and naproxen in the treatment of
      signs and symptoms of Osteoarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 13-week double-blind study followed by a 52-week, open-label, roll-over on active
      treatment study. These are randomized, parallel group, multicenter studies comparing efficacy
      and safety of naproxcinod, placebo and naproxen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to show that naproxcinod is superior to placebo in relieving OA signs and symptoms in subjects with OA of the knee at 13 weeks and to collect long term safety data</measure>
    <time_frame>13 weeks / long term</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">918</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Placebo bid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxcinod 375 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen 500 mg bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxcinod 750 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.</description>
    <arm_group_label>Placebo bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxcinod 375 mg</intervention_name>
    <arm_group_label>Naproxcinod 375 mg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <arm_group_label>Naproxen 500 mg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxcinod 750 mg</intervention_name>
    <arm_group_label>Naproxcinod 750 mg bid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women (40 or older) with a diagnosis of primary OA of the knee

          -  Must be a current chronic user of NSAIDS or acetaminophen

          -  Must discontinue all analgesic therapy at screening

        Exclusion Criteria:

          -  Uncontrolled hypertension or diabetes

          -  Hepatic or renal impairment

          -  Current or expected use of anticoagulant

          -  A history of alcohol or drug abuse

          -  Candidates for imminent joint replacement

          -  Diagnosis of gastric or duodenal ulceration and/or history of significant
             gastro-duodenal bleeding, within the last 6 months

          -  Current medical disease that could confound or interfere with the evaluation of
             efficacy

          -  Participation within 30 days prior to screening in another investigational study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2007</study_first_submitted>
  <study_first_submitted_qc>October 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2007</study_first_posted>
  <last_update_submitted>June 16, 2011</last_update_submitted>
  <last_update_submitted_qc>June 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Brigitte Duquesroix, Senior Director Clinical Research</name_title>
    <organization>NicOx</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Naproxen-n-butyl nitrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

